X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079074
https://www.expresspharma.in/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-young-children-with-hiv-in-south-africa/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213857
https://www.sciencemag.org/news/2021/08/giant-trial-covid-19-treatments-restarting-here-are-drugs-it-s-betting
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091677
https://www.europeanpharmaceuticalreview.com/news/130708/repurposed-drugs-not-effective-treatment-for-hospitalised-covid-19-patients-who-says/
http://www.koreabiomed.com/news/articleView.html?idxno=9421
https://pharmaphorum.com/news/gileads-covid-19-drug-veklury-falls-short-in-whos-global-trial/
https://www.prnewswire.co.uk/news-releases/pharming-announces-enrolment-of-first-patient-in-multinational-clinical-trial-for-the-treatment-of-covid-19-with-ruconest-r--826834736.html
https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery
https://endpts.com/covid-19-roundup-vaccines-will-need-to-beat-placebo-by-50-to-qualify-for-fda-ok-uk-trial-drops-kaletra/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/antiviral-hyped-as-potential-covid-treatment-ineffective-finds-major-study/articleshow/76703597.cms
https://www.fiercebiotech.com/biotech/after-kaletra-setback-abbvie-joins-forces-biotech-academia-for-experimental-covid-hopeful
https://www.business-standard.com/article/companies/cipla-working-on-multiple-therapies-to-fight-spread-of-coronavirus-120051701109_1.html
https://www.pharmaceutical-technology.com/news/cipla-multi-drug-combo-covid-19/
https://www.business-standard.com/article/companies/cipla-working-on-multiple-therapies-to-fight-spread-of-coronavirus-120051701109_1.html
https://www.theguardian.com/world/2020/may/14/uk-spent-20m-buying-up-stocks-of-hiv-and-malaria-drugs
https://www.clinicaltrialsarena.com/news/triple-drug-combo-covid-19/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/csir-submits-53-genome-sequences-of-coronavirus-to-global-body-to-share-450-more-by-may-15/articleshow/75595468.cms
https://news.cision.com/london-stock-exchange-faron-pharmaceuticals/r/traumakine-to-be-a-part-of-who-s-solidarity-trial,c3097227
https://www.forbes.com/sites/leahrosenbaum/2020/04/21/hiv-and-flu-drugs-prove-futile-in-fight-against-coronavirus/#5c69a93720e8
https://uk.reuters.com/article/us-health-coronavirus-russia-hiv-exclusi/exclusive-in-russia-a-black-market-for-hiv-drug-to-try-on-coronavirus-idUKKBN2220W1
https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/
https://www.reuters.com/article/us-health-coronavirus-mylan-nl/mylan-waives-exclusive-u-s-distribution-rights-for-potential-covid-19-therapy-idUSKBN21C34X?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma-asia/top-covid-19-aspirants-chloroquine-abbvie-s-kaletra-and-a-flu-drug-disappoint-clinical
https://investor.mylan.com/news-releases/news-release-details/mylan-announces-additional-efforts-support-response-covid-19
https://www.statnews.com/pharmalot/2020/03/23/abbvie-hiv-kaletra-generics-coronavirus-covid19/
https://www.reuters.com/article/us-health-coronavirus-treatment/hiv-drug-combo-fails-as-treatment-for-severe-covid-19-in-china-study-idUSKBN21544P?feedType=RSS&feedName=healthNews
http://www.pharmatimes.com/news/covid-19_cma,_nihr,_abbvie_updates_1329631
https://cen.acs.org/sections/coronavirus/biological-chemistry/infectious-disease/coronavirus-drug-repurposing.html
http://www.prnewswire.com/news-releases/lannett-announces-approval-for-lopinavir-and-ritonavir-oral-solution-usp-80-mg20-mg-per-ml-300384790.html
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207407
https://www.pharmacompass.com/pdf/news/mylan-sass-lopinavirritonavir-receive-marketing-authorisation-in-eu-for-hiv-1455104859.pdf
http://www.pharma-excipients.ch/2016/02/06/development-and-in-vivo-evaluation-of-child-friendly-lopinavir-ritonavir-pediatric-granules-utilizing-novel-in-situ-self-assembly-nanoparticles/
http://www.fiercepharma.com/story/snit-over-supply-not-prices-msf-urges-south-africa-override-abbvie-drug-pat/2015-11-03
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/government-exempts-aids-drugs-from-customs-duty/articleshow/47619068.cms
http://www.cipla.com/getattachment/50550369-81cf-4870-9d4d-58b775ccb229/Press-Release-Cipla-announces-US-FDA-approval-for-LPV-r.pdf.aspx?ext=.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205425Orig1s000TAltr.pdf
Market Place
Share 
